Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.

ABSTRACT: In recent decades, a new method of cellular immunotherapy was introduced based on engineering and empowering the immune effector cells. In this type of immunotherapy, the immune effector cells are equipped with chimeric antigen receptor (CAR) to specifically target cancer cells. In much of the trials and experiments, CAR-modified T cell immunotherapy has achieved very promising therapeutic results in the treatment of some types of cancers and infectious diseases. However, there are also some considerable drawbacks in the clinical application of CAR-T cells although much effort is in progress to rectify the issues. In some conditions, CAR-T cells initiate over-activated and strong immune responses, therefore, causing unexpected side-effects such as systemic cytokine toxicity (i.e., cytokine

SUBMITTER: Marofi F 

PROVIDER: S-EPMC7983395 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature